DRUG TARGETS FOR CYSTIC FIBROSIS AND OTHER CONDITIONS

摘要

A method of identifying agents effective in the treatment or prevention of a disorder characterised by dysfunction of ENaC comprises the step of determining the capability of a candidate agent to modulate the activity of diacylyglycerol kinase-iota (DGKι) or to modulate the activity of ciliary neurotrophic factor receptor (CNTFR). The invention further provides agents identified by such methods, the use of those agents for the treatment or prevention of a disorder characterised by dysfunction of ENaC, and pharmaceutical compositions comprising those agents. The disorder characterised by dysfunction of ENaC may be cystic fibrosis.